secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001193125-24-065913
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics reports positive Phase 2 results for paltusotine in carcinoid syndrome
--------------------------------------------------------------------------------

- Phase 2 trial: 63% reduction in mean flushing frequency (p<0.0001) for patients with >1/day at baseline.
- 60% reduction in mean excess bowel movements (p=0.02) for patients with >3/day at baseline; 61% reduction in flushing severity (p<0.0001).
- Paltusotine generally well-tolerated; no treatment-related severe or serious AEs; common AEs included diarrhea, abdominal pain, nausea, headache.
- Company plans to engage FDA to align on Phase 3 design; expects to initiate Phase 3 program by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524065913/0001193125-24-065913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524065913/d759755d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-065913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer